Lori A. Leslie, MD, discusses the current frontline treatment landscape in mantle cell lymphoma.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the current frontline treatment landscape in mantle cell lymphoma (MCL).

Treatment selection for patients with MCL is based on age, fitness, and specific diseasecharacteristics, says Leslie. Notably, a highKi67proliferation index of over 30% or a TP53 alteration, could indicate more aggressive course of disease.

Notably, a watch-and-wait approach is generally reserved for patients with indolent disease, Leslie adds.

Fit patients may receive an autologous stem cell transplant (ASCT) or dose-intensive chemotherapy, says Leslie. Sometimes, patients receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin hydrochloride, and dexamethasone may not require a consolidative transplant.

Other high-dose regimens such as dihydroxyacetone phosphateor the Nordic regimen are typically followed by ASCT, says Leslie.After transplant or high-dose chemotherapy, maintenancerituximab (Rituxan)is considered asit has been associated with overall survival benefit.

Originally posted here:
Dr. Leslie on the Current Frontline Treatment Landscape in MCL - OncLive